{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-108315","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.232187+00:00","generated_at":"2026-05-16T22:28:50.615827+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INmune Bio: CORDStrom MAA mid-2026, XPro Phase 3 in 2027; $30M cash as of Oct 14","bullets":["CORDStrom Phase 2 in RDEB improves itch/pain; MAA to UK MHRA mid-2026, BLA in US late-2026.","XPro1595 Phase 2 in early AD halts cognitive decline in biomarker-enriched patients; zero ARIA cases.","End-of-Phase-2 FDA meeting for XPro in Q1 2026; Phase 3 start planned for 2027.","Cash $30M as of Oct 14, 2025; market cap ~$50M; ~26.5M shares outstanding.","CORDStrom has Rare Pediatric Disease and Orphan Drug designations; potential PRV."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-108315","json":"https://secwatch.observer/filing/0001213900-25-108315.json","markdown":"https://secwatch.observer/filing/0001213900-25-108315.md","text":"https://secwatch.observer/filing/0001213900-25-108315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025108315/0001213900-25-108315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025108315/ea0264915-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:28:50.615827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}